辉瑞公布2026年第二季度业绩

NEW YORK, Tuesday, August 4, 2026 — Pfizer Inc. (NYSE: PFE) reported financial results for the secondquarter of 2026 and raised its full-year 2026 Revenue guidance by $500 million at the midpoint while reaffirmingguidance(2) for Adjusted(3) diluted EPS, which absorbs an impact of approximately $0.10 related to the InnoventBiologics, Inc. transaction. 

EXECUTIVE COMMENTARY 

Dr. Albert Bourla, Chairman and CEO of Pfizer:“Pfizer had another strong quarter, delivering on our financial commitments and advancing our strategy. Ourlaunched and acquired products(1) performed well, our obesity program is advancing with meaningfulmomentum and our oncology portfolio remains a source of strength. I am confident we will create substantialfuture value for patients and shareholders.” 

Cecile Guegan, Incoming Interim CFO and EVP of Pfizer:

“Our second-quarter results are attributable to our solid commercial performance globally as well as ourongoing focus on operational efficiency. This quarter, I’m particularly pleased with the 18% year-over-yearoperational revenue growth from our launched and acquired products(1). Our updated full-year 2026 guidancereflects the continued strength of and confidence in our business.” 

OVERALL RESULTS 

• Second-Quarter 2026 Revenues of $15.0 Billion, Representing 1% Year-over-Year Operational Growth 

  – Excluding Contributions from Comirnaty and Paxlovid, Revenues Grew 5% Operationally 

  – Revenues of Launched and Acquired Products(1) Grew 18% Operationally 

• Second-Quarter 2026 Reported(4) Loss Per Share of $(0.04), and Adjusted(3) Diluted EPS of $0.77– Reported(4) Loss Per Share Reflects $4.3 Billion in Non-Cash Intangible Asset Impairments 

• Announces Additional Anticipated Productivity Enhancement Savings of $2.5 Billion(5) Associated withOngoing Initiatives, Expected to be Realized From 2027 Through 2029 

• Raises Full-Year 2026 Revenue Guidance(2) by $500 Million at the Midpoint to a Range of $60.5 to $62.5Billion 

• Reaffirms Full-Year 2026 Adjusted(3) Diluted EPS Guidance in a Range of $2.80 to $3.00, which Absorbs anImpact of Approximately $0.10 Related to the Innovent Biologics, Inc. Transaction

Some amounts in this press release may not add due to rounding. All percentages have been calculated usingunrounded amounts. References to operational variances pertain to period-over-period changes that exclude theimpact of foreign exchange rates(6). 

Results for the second quarter and first six months of 2026 and 2025(7) are summarized below.

2026 FINANCIAL GUIDANCE(2) 

• Raises full-year 2026 Revenue guidance(2) by $500 million at the midpoint to a range of $60.5 to $62.5 billion,from $59.5 to $62.5 billion previously. 

  – The 2026 full-year Revenue guidance reflects better than expected performance of the non-COVIDproducts by approximately $1.5 billion and the revised revenue expectation for our COVID-19 products,down to approximately $4 billion from approximately $5 billion previously. 

• Reaffirms full-year 2026 Adjusted(3) diluted EPS guidance(2) in a range of $2.80 to $3.00. 

  – The 2026 Adjusted(3) diluted EPS guidance takes into consideration our strong year-to-date performance,continued confidence in our business and progress with ongoing cost improvement initiatives. 

  – Absorbs a $650 million Acquired In-Process R&D charge related to the completed licensing agreementwith Innovent Biologics, Inc. that will be recorded in the third quarter of 2026 with an expectedunfavorable impact of approximately $0.10

For additional details, see the attached financial schedules, product revenue tables anddisclosure notice.

(1) ‘Launched and Acquired Products’ represent select recently launched and acquired products, includingnew indications. Launched products primarily include Prevnar 20 (Pediatrics), Abrysvo (Older Adult /Maternal), Elrexfio, Cibinqo, Talzenna, Litfulo, Ngenla, Hympavzi, Penbraya Adolescent, and Lorbrena(added Q1-26); and acquired products primarily include Padcev, Adcetris, Tukysa, Tivdak, Nurtec ODT/Vydura, and Velsipity. 

(2) Pfizer does not provide guidance for U.S. generally accepted accounting principles (GAAP) Reportedfinancial measures (other than revenues) or a reconciliation of forward-looking non-GAAP financialmeasures to the most directly comparable GAAP Reported financial measures on a forward-looking basisbecause it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses,certain acquisition-related expenses, gains and losses from equity securities, actuarial gains and lossesfrom pension and postretirement plan remeasurements, potential future asset impairments and pendinglitigation without unreasonable effort. These items are uncertain, depend on various factors, and couldhave a material impact on GAAP Reported results for the guidance period.

Financial guidance for full-year 2026 reflects the following: 

▪ Does not assume the completion of any business development transactions not completed as ofAugust 4, 2026. 

▪ An anticipated unfavorable revenue impact of approximately $1.1 billion due to recent and expectedgeneric and biosimilar competition for certain products that have recently lost patent or regulatoryprotection or that are anticipated to lose patent or regulatory protection. 

▪ Exchange rates assumed are a blend of actual rates in effect through second-quarter 2026 and midJuly 2026 rates for the remainder of the year. 

▪ Guidance for Adjusted(3) diluted EPS assumes diluted weighted-average shares outstanding ofapproximately 5.74 billion shares, and assumes no share repurchases in 2026. 

(3) Adjusted income and Adjusted diluted earnings per share (EPS) are defined as U.S. GAAP net income/(loss) attributable to Pfizer Inc. common shareholders and U.S. GAAP diluted EPS/(LPS) attributable toPfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisitionrelated items, discontinued operations and certain significant items. See the accompanying reconciliationsof certain GAAP Reported to Non-GAAP Adjusted information for the second quarter and the first sixmonths of 2026 and 2025. Adjusted income and its components and Adjusted diluted EPS measures arenot, and should not be viewed as, substitutes for U.S. GAAP net income/(loss) and its components anddiluted EPS/(LPS)(4). See the Non-GAAP Financial Measure: Adjusted Income section of Management’sDiscussion and Analysis of Financial Condition and Results of Operations in Pfizer’s 2025 Annual Reporton Form 10-K and the accompanying Non-GAAP Financial Measure: Adjusted Income section of this pressrelease for a definition of each component of Adjusted income as well as other relevant information.

(4) Revenues is defined as revenues in accordance with U.S. GAAP. Reported net income/(loss) and itscomponents are defined as net income/(loss) attributable to Pfizer Inc. common shareholders and itscomponents in accordance with U.S. GAAP. Reported diluted earnings per share (EPS) and reported lossper share (LPS) are defined as diluted EPS or LPS attributable to Pfizer Inc. common shareholders inaccordance with U.S. GAAP. 

(5) Approximately $5.7 billion of overall net cost savings from Pfizer’s ongoing cost realignment program areexpected to be achieved by the end of 2026. An additional approximately $1.0 billion of anticipated net costsavings, in SI&A, is expected to be achieved from 2027 through 2029, for a total of $6.7 billion since theprogram’s inception. The additional $1.0 billion in anticipated net cost savings are calculated versus themidpoint of Pfizer’s 2026 Adjusted SI&A expense guidance reaffirmed today.Separately, the next phase of a multi-year Manufacturing Optimization Program designed to reduce ourcost of goods sold is expected to deliver net cost savings of approximately $1.5 billion through 2029, someof which is expected to begin being realized in 2027. Pfizer previously announced that it remains on trackto deliver anticipated net cost savings from the first phase of this program of approximately $1.5 billion bythe end of 2027 and, with the additional targeted savings from this phase, Pfizer now expects total net costsavings of approximately $3.0 billion from this program through 2029. 

(6) References to operational variances in this press release pertain to period-over-period changes thatexclude the impact of foreign exchange rates. Although foreign exchange rate changes are part of Pfizer’sbusiness, they are not within Pfizer’s control and because they can mask positive or negative trends in thebusiness, Pfizer believes presenting operational variances excluding these foreign exchange changesprovides useful information to evaluate Pfizer’s results.

(7) Pfizer’s fiscal year-end for international subsidiaries is November 30 while Pfizer’s fiscal year-end for U.S.subsidiaries is December 31. Therefore, Pfizer’s second quarter and first six months for U.S. subsidiariesreflects the three and six months ended on June 28, 2026 and June 29, 2025, while Pfizer’s secondquarter and first six months for subsidiaries operating outside the U.S. reflects the three and six monthsended on May 24, 2026 and May 25, 2025.